Wholomics @ LSI USA ’25

Wholomics Unveils Groundbreaking Early Cancer Detection Technology at LSI USA ’25
Innovative Multi-Omics Platform Set to Transform Cancer Diagnostics

Dana Point, CA – 03/17/2025 – Wholomics, a pioneering early cancer detection company, is excited to announce its presence at LSI USA ’25, Medtech’s premier partnering event held at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, California. At the conference, Wholomics will showcase its innovative NMR-based multi-omics platform that enables minimally invasive blood tests to detect multiple cancers at their earliest, most treatable stages.

“Our technology represents a seismic shift in cancer diagnostics,” said Patrick Strasser, CEO of Wholomics. “By harnessing advanced metabolomic, proteomic, and lipidomics analyses, we are able to detect the subtle molecular signals of early-stage cancer with unprecedented sensitivity. At LSI USA ’25, we’re excited to demonstrate how our breakthrough platform can redefine patient care and ultimately save lives.”

Wholomics’ solution addresses the critical problem of late-stage cancer diagnosis—a challenge that has long limited treatment effectiveness and survival rates. Early clinical studies have shown exceptional accuracy in detecting cancers of multiple cancers such as ovarian, pancreatic, and colorectal cancer, offering new hope for high-risk populations. The company’s innovative approach not only promises to improve patient outcomes but also to reduce the financial burden on healthcare systems by enabling earlier, more cost-effective interventions.

At LSI USA ’25, Wholomics will engage with global Medtech and Healthtech leaders, investors, and strategic partners to explore collaboration opportunities that will further accelerate the path to market for its life-saving tests. The company’s participation in this event underscores its commitment to advancing early cancer detection technologies and setting new standards in the field.

For more information about Wholomics and to schedule a meeting at LSI USA ’25, please visit www.wholomics.com/landing or contact our media relations team at info@wholomics.com.

About Wholomics
Founded and based in Austria, Wholomics is revolutionizing early cancer detection through its innovative multi-omics platform. By integrating metabolomic, proteomic, and lipidomic analyses with advanced AI, Wholomics delivers minimally invasive blood tests with high sensitivity and specificity for detecting multiple cancers at their earliest stages. With a mission to transform cancer diagnostics and improve patient outcomes worldwide, Wholomics is forging new pathways in preventive healthcare.

Contact:
Patrick Strasser
Co-Founder & CEO
Wholomics
+1 617 222 0055 / + 43 664 918 2336
info@wholomics.com
www.wholomics.com